MAP3K8 is a Potential Therapeutic Target in Airway Epithelial Inflammation

Overview

Journal J Inflamm (Lond)

Publisher Biomed Central

Date 2024 Jul 19

PMID 39030600

Authors

Chih-Yung Chiu

Saffron A G Willis-Owen

Kenny C C Wong

Stuart N Farrow

William O C Cookson

Miriam F Moffatt

Youming Zhang

Affiliations

Soon will be listed here.

Abstract

Background: We have previously discovered clusters of sequentially negative and positive modulators of acute inflammation during cytokine stimulation in epithelial cells and identified potential targets for therapy within these clusters. MAP3K8 is a druggable kinase that we found to be a hub of a principal interaction network. We describe here the results of MAP3K8 knockdown in the A549 lung cancer cell line, the BEAS-2B epithelial cell line and normal human bronchial epithelial (NHBE) cells following IL-1β stimulation. We analysed signalling transduction and global gene expression after IL-1β stimulation with and without MAP3K8 knockdown, quantifying levels of the inflammatory cytokines IL-6, IL-8 and RANTES levels by qPCRs and/or by ELISAs. We also examined potential small molecule inhibitors for MAP3K8 in the same models.

Results: IL-1β significantly and consistently increased MAP3K8 expression after 2 h in A549, BEAS-2B and NHBE cells. Phosphorylation of MAP3K8 occurred at 20 min after IL-1β stimulation and MAP3K8 protein was degraded at 30 min. MAP3K8 knockdown significantly reduced IL-6, IL-8 levels after IL-1β stimulation and yielded a 10-fold enhancement of the anti-inflammatory effects of dexamethasone. Phosphorylation of ERK1/2 (P-ERK1/2) and phosphorylation of SAPK/JNK (P-SAPK/JNK) decreased at 30 min after IL-1β stimulation with MAP3K8 knockdown. The combination of dexamethasone and MAP3K8 knockdown resulted in greater inhibition of phosphorylated ERK1/2 and SAPK/JNK. Nineteen genes including MMP1, MMP3, MMP10, ITGB8, LAMC2 and PLAT (P corrected < 0.01 respectively) demonstrated a distinct altered temporal response to IL-1β following suppression of MAP3K8. However, putative MAP3K8 inhibitors including Tpl2-1, Tpl2-2 and GSK2222867A only showed inhibition of IL-6 and IL-8 production at a high dose.

Conclusions: These results confirm that MAP3K8 is a key mediator of the early inflammatory response and that it is a potential target in inflammatory diseases. However, current tool compounds do not effectively inhibit its effects.

References

Vougioukalaki M, Kanellis D, Gkouskou K, Eliopoulos A . Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett. 2011; 304(2):80-9. DOI: 10.1016/j.canlet.2011.02.004. View

Dumitru C, Ceci J, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin J . TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell. 2001; 103(7):1071-83. DOI: 10.1016/s0092-8674(00)00210-5. View

Cohen P . Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol. 2009; 21(2):317-24. DOI: 10.1016/j.ceb.2009.01.015. View

Liu W, Liang Q, Balzar S, Wenzel S, Gorska M, Alam R . Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol. 2008; 121(4):893-902.e2. DOI: 10.1016/j.jaci.2008.02.004. View

Rodriguez C, Pozo M, Nieto E, Fernandez M, Alemany S . TRAF6 and Src kinase activity regulates Cot activation by IL-1. Cell Signal. 2005; 18(9):1376-85. DOI: 10.1016/j.cellsig.2005.10.016. View

Lang V, Symons A, Watton S, Janzen J, Soneji Y, Beinke S . ABIN-2 forms a ternary complex with TPL-2 and NF-kappa B1 p105 and is essential for TPL-2 protein stability. Mol Cell Biol. 2004; 24(12):5235-48. PMC: 419892. DOI: 10.1128/MCB.24.12.5235-5248.2004. View

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

Gantke T, Sriskantharajah S, Sadowski M, Ley S . IκB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev. 2012; 246(1):168-82. DOI: 10.1111/j.1600-065X.2012.01104.x. View

Zhang Y, Willis-Owen S, Spiegel S, Lloyd C, Moffatt M, Cookson W . The ORMDL3 Asthma Gene Regulates ICAM1 and Has Multiple Effects on Cellular Inflammation. Am J Respir Crit Care Med. 2018; 199(4):478-488. PMC: 6376621. DOI: 10.1164/rccm.201803-0438OC. View

10.

Sandhu G, Thelma B . New Druggable Targets for Rheumatoid Arthritis Based on Insights From Synovial Biology. Front Immunol. 2022; 13:834247. PMC: 8899708. DOI: 10.3389/fimmu.2022.834247. View

11.

Sriskantharajah S, Guckel E, Tsakiri N, Kierdorf K, Brender C, Ben-Addi A . Regulation of experimental autoimmune encephalomyelitis by TPL-2 kinase. J Immunol. 2014; 192(8):3518-3529. PMC: 3979668. DOI: 10.4049/jimmunol.1300172. View

12.

Dougherty M, Ritt D, Zhou M, Specht S, Monson D, Veenstra T . KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals. Mol Cell. 2009; 34(6):652-62. PMC: 2737517. DOI: 10.1016/j.molcel.2009.06.001. View

13.

Xu D, Matsumoto M, McKenzie B, Zarrin A . TPL2 kinase action and control of inflammation. Pharmacol Res. 2017; 129:188-193. DOI: 10.1016/j.phrs.2017.11.031. View

14.

Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64. DOI: 10.1093/biostatistics/4.2.249. View

15.

Das S, Cho J, Lambertz I, Kelliher M, Eliopoulos A, Du K . Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J Biol Chem. 2005; 280(25):23748-57. DOI: 10.1074/jbc.M412837200. View

16.

Eliopoulos A, Wang C, Dumitru C, Tsichlis P . Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J. 2003; 22(15):3855-64. PMC: 169059. DOI: 10.1093/emboj/cdg386. View

17.

Chiba N, Kakimoto K, Masuda A, Matsuguchi T . Functional roles of Cot/Tpl2 in mast cell responses to lipopolysaccharide and FcεRI-clustering. Biochem Biophys Res Commun. 2010; 402(1):1-6. DOI: 10.1016/j.bbrc.2010.08.075. View

18.

Benjamini Y, Cohen R . Weighted false discovery rate controlling procedures for clinical trials. Biostatistics. 2016; 18(1):91-104. PMC: 5255051. DOI: 10.1093/biostatistics/kxw030. View

19.

Bhavsar P, Hew M, Khorasani N, Torrego A, Barnes P, Adcock I . Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax. 2008; 63(9):784-90. DOI: 10.1136/thx.2007.090027. View

20.

Dennis Jr G, Sherman B, Hosack D, Yang J, Gao W, Lane H . DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5):P3. View